Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.

Lijing Ye, Lejing Lou, Zhangyong Yin, Ting He, Xiaoping Cai

Abstract read

In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lijing YeDepartment of Pulmonary and Critical Care Medicine, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, No. 1188 Liyang Street, Liandu District, Lishui, Zhejiang, 323000, China.

Lejing LouDepartment of Pulmonary and Critical Care Medicine, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, No. 1188 Liyang Street, Liandu District, Lishui, Zhejiang, 323000, China.

Zhangyong YinDepartment of Pulmonary and Critical Care Medicine, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, No. 1188 Liyang Street, Liandu District, Lishui, Zhejiang, 323000, China.

Ting HeDepartment of Pulmonary and Critical Care Medicine, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, No. 1188 Liyang Street, Liandu District, Lishui, Zhejiang, 323000, China.

Xiaoping CaiDepartment of Pulmonary and Critical Care Medicine, Lishui Hospital of Wenzhou Medical University, The First Affiliated Hospital of Lishui University, Lishui People's Hospital, No. 1188 Liyang Street, Liandu District, Lishui, Zhejiang, 323000, China. xiaopingcai546@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant pleural effusion (MPE) is a common and serious manifestation of advanced non-small cell lung cancer (NSCLC). This study aimed to retrospectively evaluate the efficacy and safety of thoracoscopic photodynamic therapy (PDT) combined with 5% ethanol-cisplatin intrapleural perfusion compared to cisplatin intrapleural perfusion or drainage alone.

methodsThis retrospective study analyzed 122 NSCLC patients with MPE who had failed first-line chemotherapy. Patients were divided into three groups: PDT combined with 5% ethanol-cisplatin (PDT + E-Cis, n = 32), intrapleural cisplatin perfusion (IP-Cis, n = 39), and drainage alone control (Control, n = 51). All patients received systemic chemotherapy with docetaxel. Observation endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety.

resultsAt week 12, the ORR of the PDT + E-Cis group was 75.0%, significantly higher than that of the IP-Cis group (43.6%) and the Control group (17.6%) (All P < 0.05). Survival analysis showed that the median PFS of the PDT + E-Cis group (6.13 months) was significantly longer than that of the Control group (3.48 months, P = 0.005), but showed no statistical difference compared to the IP-Cis group (4.21 months, P = 0.229). The median OS (14.17 months) was significantly superior to that of the Control group (8.88 months, P < 0.001) and showed a trend towards prolongation compared to the IP-Cis group (11.23 months, P = 0.033). Regarding safety, the incidence of chest pain and fever in the PDT + E-Cis group was higher than in the Control group but similar to the IP-Cis group. Most adverse events were grade 1–2, with no treatment-related deaths or severe adverse events occurring.

conclusionThoracoscopic PDT combined with 5% ethanol-cisplatin intrapleural perfusion demonstrates favorable safety and efficacy. It can significantly improve the local control rate of MPE in NSCLC and shows clinical potential for prolonging patient survival.

Indexed as

Carcinoma, Non-Small-Cell LungCisplatinEthanolLung NeoplasmsPhotochemotherapyPleural Effusion, MalignantThoracoscopyAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeCisplatinEthanol5% ethanolCisplatinMalignant pleural effusionNon-small cell lung cancerPhotodynamic therapy

Identifiers

PMID41928174

DOI10.1186/s12885-026-15919-1

PMCPMC13169524

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.